DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer. Experienced team of individuals with expertise…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.